The dual blockade of the renin-angiotensin system in hemodialysis patients requires decreased dialysate sodium concentration
- PMID: 23136031
- PMCID: PMC3825035
- DOI: 10.1007/s11255-012-0320-z
The dual blockade of the renin-angiotensin system in hemodialysis patients requires decreased dialysate sodium concentration
Abstract
Purpose: The study evaluated whether the dual blockade of the renin-angiotensin system may influence the sodium balance in hemodialysis.
Methods: The study involved 148 hemodialysis patients (male 85, female 63), mean age 59.6 ± 12.9 years. Participants were randomly selected to receive either angiotensin-converting enzyme inhibitor (ACEI)--subgroup A--or dual blockade ACEI and angiotensin receptor blocker (ARB)--subgroup AA.
Results: At baseline, in the A versus AA subgroups, the pre-dialysis sodium concentrations (mmol/l) were 137.7 ± 0.5 versus 137.9 ± 0.8, the sodium gradients 2.6 ± 0.5 versus 2.9 ± 0.4, interdialytic weight gain (IWG) (kg) 3.1 ± 0.2 versus 3.0 ± 0.3, and thirst inventory score (points) 18.1 ± 1.0 versus 19.0 ± 1.7, respectively. After 3 months of therapy, a decrease in sodium concentration to 134.5 ± 0.5 and the increase of its gradient to 5.5 ± 0.5 were noted in the AA subgroup. An elevation of mean interdialytic weight gain to 3.47 ± 0.2 and thirst score to 21.3 ± 2.1 was observed. No significant changes in subgroup A were found. One month of the dialysate sodium concentration being lowered from 140 mmol/l to 138 mmol/l was associated with reduced serum sodium concentration and gradient, decreased IWG and restored moderate thirst score in the AA subgroup (137.5 ± 0.6 and 2.9 ± 0.6, 3.0 ± 0.5 and 19.2 ± 1.3, respectively).
Conclusions: The dual blockade of the renin-angiotensin system affects sodium balance, increasing the sodium gradient, thus elevating thirst sensation and enhancing interdialytic weight gain. In maintenance hemodialysis patients treated with both ACEI and ARB, lowered dialysate sodium levels should be prescribed.
Figures
Similar articles
-
Influence of dual blockade of the renin-angiotensin system on thirst in hemodialysis patients.Nephron Clin Pract. 2009;112(4):c242-7. doi: 10.1159/000224790. Epub 2009 Jun 16. Nephron Clin Pract. 2009. PMID: 19546583 Clinical Trial.
-
Use of Renin-Angiotensin System Blockers Increases Serum Potassium in Anuric Hemodialysis Patients.Am J Nephrol. 2018;48(2):79-86. doi: 10.1159/000491552. Epub 2018 Aug 2. Am J Nephrol. 2018. PMID: 30071530
-
Lack of effect of long-term use of angiotensin-converting enzyme inhibitors by hemodialysis patients on thirst and fluid weight gain.Ren Fail. 2002 Jul;24(4):461-6. doi: 10.1081/jdi-120006772. Ren Fail. 2002. PMID: 12212825 Clinical Trial.
-
Thirst, interdialytic weight gain, and thirst-interventions in hemodialysis patients: a literature review.Nephrol Nurs J. 2001 Dec;28(6):601-4, 610-3; quiz 614-5. Nephrol Nurs J. 2001. PMID: 12143470 Review.
-
Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.Am J Cardiovasc Drugs. 2019 Jun;19(3):259-286. doi: 10.1007/s40256-018-00321-5. Am J Cardiovasc Drugs. 2019. PMID: 30737754
Cited by
-
Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitor in Combination with Angiotensin-Receptor Blocker in Chronic Kidney Disease Based on Dose: A Systematic Review and Meta-Analysis.Front Pharmacol. 2021 May 6;12:638611. doi: 10.3389/fphar.2021.638611. eCollection 2021. Front Pharmacol. 2021. PMID: 34025408 Free PMC article.
-
Sodium gradient, xerostomia, thirst and inter-dialytic excessive weight gain: a possible relationship with hyposalivation in patients on maintenance hemodialysis.Int Urol Nephrol. 2014 Jul;46(7):1411-7. doi: 10.1007/s11255-013-0576-y. Epub 2013 Oct 6. Int Urol Nephrol. 2014. PMID: 24096371 Free PMC article.
-
Practice patterns in transitioning patients from chronic kidney disease to dialysis: a survey of United States nephrologists.BMC Nephrol. 2018 Jun 22;19(1):147. doi: 10.1186/s12882-018-0943-0. BMC Nephrol. 2018. PMID: 29929485 Free PMC article.
-
A potential link between AQP3 and SLC14A1 gene expression level and clinical parameters of maintenance hemodialysis patients.BMC Nephrol. 2022 Aug 29;23(1):297. doi: 10.1186/s12882-022-02922-4. BMC Nephrol. 2022. PMID: 36038817 Free PMC article.
-
Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass.BMC Nephrol. 2013 Jul 15;14:149. doi: 10.1186/1471-2369-14-149. BMC Nephrol. 2013. PMID: 23855560 Free PMC article. Clinical Trial.
References
-
- Keen ML, Gotch FA. The association of sodium setpoint to interdialytic weight gain and blood pressure in hemodialysis patients. Int J Artif Organs. 2007;30:971–979. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical